1. Signaling Pathways
  2. Stem Cell/Wnt
  3. β-catenin

β-catenin

Beta catenin

β-catenin is a dual function protein, regulating the coordination of cell–cell adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1 gene. β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway. It is a member of the catenin protein family and homologous to γ-catenin. Mutations and overexpression of β-catenin are associated with many cancers, including hepatocellular carcinoma, colorectal carcinoma, lung cancer,malignant breast tumors, ovarian and endometrial cancer. β-catenin is regulated and destroyed by the beta-catenin destruction complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the tumour-suppressing APC gene. Therefore genetic mutation of the APC gene is also strongly linked to cancers, and in particular colorectal cancer resulting from familial adenomatous polyposis (FAP).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990501
    Anti-RSPO1 Antibody
    Inhibitor
    Anti-RSPO1 Antibody is a humanized antibody expressed in CHO that targets RSPO1. The Anti-RSPO1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-RSPO1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-RSPO1 Antibody
  • HY-12643R
    Eprinomectin (Standard)
    Eprinomectin (Standard) is the analytical standard of Eprinomectin. This product is intended for research and analytical applications. Eprinomectin is a type of avermectin. Eprinomectin, as a broad-spectrum fungicide, has insecticidal, insecticidal and acaricidal activities. Eprinomectin induces apoptosis and autophagy in prostate cancer cells and has antitumor activity.
    Eprinomectin (Standard)
  • HY-113680
    KY1022
    Degrader
    KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer.
    KY1022
  • HY-175177
    XIAP-CASP7 PPI-IN-1
    Inhibitor
    Xiap-casp7 PPI-IN-1 is a reversible XIAP: CASP7 inhibitor with specifically disrupting the interaction between XIAP and CASP7. XIAP-CASP7 PPI-IN-1 selectively induce MCF-7 and other caspase-3 down-regulation (CASP3/DR) triple-negative breast cancer cell apoptosis. XIAP-CASP7 PPI-IN-1 overcomes chemoresistance via down-regulating β-catenin and its associated ABC transporters in Paclitaxel (HY-B0015)-resistant MCF-7 cells. XIAP-CASP7 PPI-IN-1 can be used for the study of breast cancer.
    XIAP-CASP7 PPI-IN-1
  • HY-176713
    KWZY-11
    Inhibitor
    KWZY-11 (Compound 11) is a potent PARP/CDK6 dual inhibitor with IC50 values of 156.8, 197.3, and 13.3 nM for PARP1, PARP2, and CDK6, respectively. KWZY-11 inhibits tumor cell proliferation by regulating the Wnt/β-catenin signaling pathway. KWZY-11 induces excessive DNA damage and apoptosis in MDA-MB-231 breast cancer cells.
    KWZY-11
  • HY-B0012B
    Pamidronic acid sodium
    Inhibitor
    Pamidronic acid sodium, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid sodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid sodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma.
    Pamidronic acid sodium
  • HY-W002112S1
    (±)-Nornicotine-d7
    Inhibitor
    (±)-Nornicotine-d7 is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia.
    (±)-Nornicotine-d<sub>7</sub>
  • HY-153681
    β-Catenin modulator-4
    Modulator
    β-Catenin modulator-4 (compound IIa-92), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator.
    β-Catenin modulator-4
  • HY-153214
    YW2036
    Inhibitor 99.48%
    YW2036 (compound 2a) is a potent Wnt/β-Catenin signaling pathway inhibitor with an IC50 value of 637 nM. YW2036 can be used in research of colorectal cancer (CRC).
    YW2036
  • HY-124826
    BC21
    Inhibitor
    BC21 (NSC 109268) is a β-catenin/Tcf4 inhibitor with an IC50 of 5 μM. BC21 effectively inhibits the binding of β-catenin to Tcf4-derived peptides and suppresses β-catenin/Tcf4-driven reporter gene activity. BC21 can be utilized in cancer research.
    BC21
  • HY-P10652
    hsBCL9CT-24
    Inhibitor
    hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research.
    hsBCL9CT-24
  • HY-141543
    YW2065
    Inhibitor 99.91%
    YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of wnt/β-catenin signaling inhibition and AMPK activation.
    YW2065
  • HY-151463A
    CDK8-IN-11 hydrochloride
    Inhibitor
    CDK8-IN-11 hydrochloride is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM. CDK8-IN-11 hydrochloride inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 hydrochloride can be used in the research of colon cancer.
    CDK8-IN-11 hydrochloride
  • HY-153679
    β-Catenin modulator-2
    Modulator
    β-Catenin modulator-2 (compound IIa-130), an oxazole and thiazole compound, is a potent and selective β-Catenin modulator.
    β-Catenin modulator-2
  • HY-161087
    β-catenin/BCL9 PPI-IN-1
    Inhibitor
    β-catenin/BCL9 PPI-IN-1 (compound B4) is a potent inhibitor of β catenin/B-Cell lymphoma 9 protein?protein interaction (β catenin/BCL9 PPI) with the IC50 value of 2.25 μM.
    β-catenin/BCL9 PPI-IN-1
  • HY-B1057S2
    Nefopam-d3
    Inhibitor
    Nefopam-d3 is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells.
    Nefopam-d<sub>3</sub>
  • HY-157990
    Wnt/β-catenin-IN-1
    Inhibitor
    Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors.
    Wnt/β-catenin-IN-1
  • HY-129566R
    Withanolide B (Standard)
    Activator
    Withanolide B (Standard) is the analytical standard of Withanolide B. This product is intended for research and analytical applications. Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects.
    Withanolide B (Standard)
  • HY-153678
    β-Catenin modulator-1
    Modulator
    β-Catenin modulator-1 (IIa-650) is a β-Catenin modulator useful in cancer research.
    β-Catenin modulator-1
  • HY-B0194AS
    Tizanidine-d4 hydrochloride
    Inhibitor
    Tizanidine-d4 hydrochloride is deuterium labeled Tizanidine hydrochloride (HY-B0194A). Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α2-adrenoceptor agonist (IC50 = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).
    Tizanidine-d<sub>4</sub> hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity